# Zura Bio Limited Class A Ordinary Shares (ZURA)

> Zura Bio Limited Class A Ordinary Shares (ZURA) trades at $0.9608 (-7.17%) as of 7:15:57 AM EST on Nov 19, 2026, -75.87% over the past month. Market cap is $92.96M, with 1.8 days to cover in short interest.

Canonical: https://massive.com/quote/zura
Data as of: 2026-11-19T12:15:57.369Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$0.9608** -0.07 (-7.17%)
As of 7:15:57 AM EST on Nov 19, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Zura Bio Limited Class A Ordinary Shares (ZURA) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -6.75% |
| 1W | -32.51% |
| 1M | -75.87% |
| YTD | -81.58% |
| 1Y | -73.70% |
| 52-wk range | $0.93 – $7.44 |

From daily closes through Nov 18, 2026.

## Key statistics

Today's trading snapshot for ZURA: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $0.94 – $1.05 |
| Open | $1.01 |
| Prev close | $1.04 |
| Volume | 3.03M |
| Market cap | $92.96M |
| Shares out | 96.33M |

## Valuation and profitability ratios

Valuation and profitability ratios for Zura Bio Limited Class A Ordinary Shares: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 0.53 |
| P/FCF | — |
| ROE | -68.8% |
| ROA | -62.8% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 18, 2026

## Insider trading

[Zura Bio Limited Class A Ordinary Shares (ZURA) insider trading](https://massive.com/quote/zura/insider-trading.md): open-market Form 4 buys and sells by Zura Bio Limited Class A Ordinary Shares insiders over the last 12 months.

## 8-K filings

Material corporate events Zura Bio Limited Class A Ordinary Shares has disclosed to the SEC on Form 8-K.

- Oct 27, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On October 27, 2026, Zura Bio Limited (the "Company") issued a press release announcing its third quarter 2026 financial results.”
- Aug 17, 2026 · Investor presentation
  “On August 17, 2026, Zura Bio Limited (the "Company") provided an updated corporate presentation that may be used in connection with upcoming presentations at conferences and investor meetings. The full text of the Company's corporate presentation is filed as Exhibit 99.1 hereto.”
- Aug 11, 2026 · Investor presentation
  “On August 11, 2026, the Company provided an updated corporate presentation that may be used in connection with upcoming presentations at conferences and investor meetings.”
- Jul 1, 2026 · Investor presentation
  “On July 1, 2026, Zura Bio Limited (the "Company") provided an updated corporate presentation that may be used in connection with upcoming presentations at conferences and investor meetings. The full text of the Company's corporate presentation is furnished as Exhibit 99.1 hereto.”
- Jun 18, 2026 · Annual meeting results
  “On June 17, 2026, the Company held its Annual General Meeting of Shareholders (the "Annual Meeting"), at which a quorum was present. At the Annual Meeting, the shareholders of the Company voted on the following four proposals: (1) the election, by ordinary resolution, of the eight (8) directors listed below (the "Director Nominees") to the Company's Board of Directors (the "Board")... The final results of the voting on each proposal are set forth below.”

## ZURA short interest

How heavily ZURA is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 1.8 |
| Short interest | 8.47M |
| Avg volume | 4.73M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## ZURA news

The latest news and headlines about Zura Bio Limited Class A Ordinary Shares (ZURA).

- [JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering](https://www.benzinga.com/pressreleases/26/04/g51926686/jatt-ii-acquisition-corp-announces-closing-of-60-000-000-initial-public-offering?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Apr 20, 2026 · positive sentiment
- [Hidradenitis Suppurativa Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 24+ Companies and 26+ Therapies \| DelveInsight](https://www.globenewswire.com/news-release/2025/10/23/3172338/0/en/Hidradenitis-Suppurativa-Clinical-Trial-Analysis-Key-Insights-into-Rich-Pipeline-Featuring-24-Companies-and-26-Therapies-DelveInsight.html) · GlobeNewswire Inc. · Oct 23, 2025 · positive sentiment
- [12 Health Care Stocks Moving In Monday's Intraday Session](https://www.benzinga.com/insights/penny-stocks/25/09/47923550/12-health-care-stocks-moving-in-mondays-intraday-session) · Benzinga · Sep 29, 2025 · positive sentiment
- [Wall Street Analysts Predict a 235.2% Upside in Zura Bio Limited (ZURA): Here's What You Should Know](https://www.zacks.com/stock/news/2282046/wall-street-analysts-predict-a-2352-upside-in-zura-bio-limited-zura-heres-what-you-should-know) · Zacks Investment Research · May 31, 2024
- [How Much Upside is Left in Zura Bio Limited (ZURA)? Wall Street Analysts Think 248.84%](https://www.zacks.com/stock/news/2274181/how-much-upside-is-left-in-zura-bio-limited-zura-wall-street-analysts-think-24884) · Zacks Investment Research · May 15, 2024

## About Zura Bio Limited Class A Ordinary Shares

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 40 |
| Listed | Mar 21, 2023 |

[Company website](https://www.zurabio.com)

## FAQ

### What is the Zura Bio Limited Class A Ordinary Shares (ZURA) stock price today?

Zura Bio Limited Class A Ordinary Shares (ZURA) is trading at $0.9608 (-7.17% on the day) as of 7:15:57 AM EST on Nov 19, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Zura Bio Limited Class A Ordinary Shares?

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need.

### What is the short interest in ZURA?

As of Oct 30, 2026, ZURA has 8.47M shares short and 1.8 days to cover.

### What exchange is ZURA listed on?

Zura Bio Limited Class A Ordinary Shares (ZURA) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

## Live data

Prices here are 15-minute delayed. For real-time ZURA quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=ZURA`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Zura Bio Limited Class A Ordinary Shares (ZURA) insider trading](https://massive.com/quote/zura/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
